The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Astellas Pharma
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Johnson & Johnson; MSD Oncology; Pfizer; Roche; Sanofi
Speakers' Bureau - Asofarma; Astellas Pharma; Bayer; Johnson & Johnson
Research Funding - AB Science; Aragon Pharmaceuticals; Arog; Astellas Pharma; AstraZeneca; AVEO; Bayer; Blueprint Medicines; BN ImmunoTherapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Cougar Biotechnology; Deciphera; Exelixis; F. Hoffmann LaRoche; Genentech; GlaxoSmithKline; Incyte; Janssen-Cilag; Karyopharm Therapeutics; Laboratories Leurquin Mediolanum; Lilly; MedImmune; Millenium Pharamceuticals; Nanobiotix; Novartis; Pfizer; Puma Biotechnology; S.L.U; Sanofi; SFJ Pharmaceuticals Group; Teva
Expert Testimony - Othera
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Ipsen; Roche
A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Foundation Medicine; Foundation One Inc; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Arun Azad
Honoraria - Astellas Pharma; Janssen; Novartis
Consulting or Advisory Role - Astellas Pharma; Novartis
Speakers' Bureau - Janssen
Research Funding - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma
 
Joan Carles
No Relationships to Disclose
 
Simon Chowdhury
Honoraria - Clovis Oncology; Novartis
Consulting or Advisory Role - Astellas Pharma; Bayer; Clovis Oncology; Janssen-Cilag; Pfizer
Speakers' Bureau - Pfizer
Research Funding - Sanofi (Inst)
 
Bradley Alexander McGregor
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Eisai; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Nextar; Pfizer; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Seattle Genetics/Astellas (Inst)
 
Axel Stuart Merseburger
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen-Cilag; MSD Oncology
Speakers' Bureau - Ipsen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Janssen-Cilag (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Janssen-Cilag
 
Stephane Oudard
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD Oncology; MSD Oncology; Novartis; Pfizer; Roche; Roche; Sanofi
Research Funding - Ipsen; Sanofi
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck; MSD Oncology; Novartis; Pfizer; Roche
 
Fred Saad
Honoraria - Abbvie; Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Myovant Sciences; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Myovant Sciences; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Pfizer (Inst); Sanofi (Inst)
 
Andrey Soares
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; MSD; Pfizer; Roche; Sanofi
 
Ashok Panneerselvam
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Fong Wang
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
Travel, Accommodations, Expenses - Exelixis
 
Sumanta K. Pal
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer